Celsion Corporation (NASDAQ:CLSN) Shorts Decreased By 16.67%

April 16, 2018 - By Michael Higginson

Celsion Corporation (NASDAQ:CLSN) Corporate Logo

Celsion Corporation (NASDAQ:CLSN) showed a decrease of 16.67% in shares shorted. It was announced in April by FINRA the 1.11 million shares shorted on CLSN. The down change of 16.67% from 1.33 million shares was reported. With Average volume 313,600, CLSN’s previous position will take 4 days to recover.

Its shares touched $2.253 on during the last trading session after 1.60% change.Celsion Corporation has volume of 76,830 shares. Since April 16, 2017 CLSN has declined 35.14% and is downtrending. The stock underperformed the S&P500 by 46.69%.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.The firm is worth $39.98 million. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.Currently it has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: